In conclusion, TIGIT, but not PD-1, was expressed on activated CD8+ T cells in the PBSC grafts of patients with MM and our preclinical data highlight that the antimyeloma efficacy of TIGIT inhibition was highly dependent on FcγR engagement. This evidence concerns the gene CD8A and Miyoshi myopathy.